HBM HEALTHCARE INVESTMENTS AG

(HBMN)
  Report
Delayed Swiss Exchange  -  11:31 2022-06-29 am EDT
272.00 CHF   -0.18%
06/17Key Figures 15.06.2022
EQ
06/10Shareholders' Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors
EQ
06/10HBM Healthcare Investments AG Approves Distribution, Payable on 1 September 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal

05/10/2022 | 12:27pm EDT

HBM Healthcare Investments AG / Key word(s): Acquisition
Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal

10.05.2022 / 18:25


HBM Healthcare Investments today announces that its portfolio company Biohaven Pharmaceuticals (NYSE: BHVN) will be acquired by Pfizer (NYSE: PFE) for USD 11.6 billion in cash. The acquisition price of USD 148.50 per Biohaven share represents a premium of approximately 78 percent to the closing share price on 9 May 2022. Biohaven shareholders will also receive shares in "New Biohaven", a new publicly traded company that will retain Biohaven's non-CGRP pipeline compounds in development.

HBM Healthcare Investments holds around 0.45 million shares in Biohaven with a total value of USD 67 million based on the acquisition price. Following the acquisition of Sierra Oncology by GlaxoSmithKline in April and of Zogenix by UCB in January, this is the third acquisition from HBM Healthcare Investments' portfolio of listed companies in the current calendar year 2022.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.



End of Media Release


Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1348797

 
End of News EQS News Service

1348797  10.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1348797&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about HBM HEALTHCARE INVESTMENTS AG
06/17Key Figures 15.06.2022
EQ
06/10Shareholders' Meeting of HBM Healthcare Investments approved all proposals by the Board..
EQ
06/10HBM Healthcare Investments AG Approves Distribution, Payable on 1 September 2022
CI
06/03Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for US..
EQ
06/01HBM HEALTHCARE INVESTMENTS : Key Figures 31.05.2022
PU
06/01Key Figures 31.05.2022
EQ
05/18HBM Healthcare Investments AG Reports Earnings Results for the Full Year Ended March 31..
CI
05/18Publication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders? Mee..
EQ
05/16Key Figures 15.05.2022
EQ
05/10Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion de..
EQ
More news
Analyst Recommendations on HBM HEALTHCARE INVESTMENTS AG
More recommendations
Financials
Sales 2023 170 M 178 M 178 M
Net income 2023 122 M 128 M 128 M
Net cash 2023 35,0 M 36,7 M 36,7 M
P/E ratio 2023 15,5x
Yield 2023 3,57%
Capitalization 1 892 M 1 984 M 1 984 M
EV / Sales 2023 10,9x
EV / Sales 2024 7,56x
Nbr of Employees 700
Free-Float 82,7%
Chart HBM HEALTHCARE INVESTMENTS AG
Duration : Period :
HBM Healthcare Investments AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HBM HEALTHCARE INVESTMENTS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 272,00 CHF
Average target price 292,00 CHF
Spread / Average Target 7,35%
EPS Revisions
Managers and Directors
Andreas Wicki Chief Executive Officer
Erwin Troxler Chief Financial Officer
Hans-Peter Hasler Chairman
Rudolf Lanz Director
Mario Germano Giuliani Director